BRIEF — Verastem To Open TARGET — D 301 1L mPDAC Trial By Year — End 2026

Oct 14 (Reuters) — Verastem Inc: Versus-7375 Demonstrates Robust Anti-tumor Activity Across Advanced Kras G12d-mutant Cancers, Highlighted By 50% Confirmed Orr In 2l Pancreatic Ductal Adenocarcinoma And Two Complete Responses In 2l+ Disease (One Confirmed) Verastem - To Open Target-d 301 1l Mpdac Trial By Year-end 2026 Verastem - Versus-7375 900 Mg Qd Monotherapy Achieves 41% Confirmed Orr In 2l+ Pdac Verastem Inc: Expect To Report Initial Data From 1l Mpdac Combination With Gnp In Q1 2027 Source text:... Further company coverage: VSTM.O (Reuters.Briefs@thomsonreuters.com;)